Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):316-325. doi: 10.1002/psp4.12400. Epub 2019 Apr 9.
Drug-induced kidney injury, a major cause of acute kidney injury, results in progressive kidney disease and is linked to increased mortality in hospitalized patients. Primary injury sites of drug-induced kidney injury are proximal tubules. Clinically, kidney injury molecule-1, an established tubule-specific biomarker, is monitored to assess the presence and progression of injury. The ability to accurately predict drug-related nephrotoxicity preclinically would reduce patient burden and drug attrition rates, yet state-of-the-art in vitro and animal models fail to do so. In this study, we demonstrate the use of kidney injury molecule-1 measurement in the kidney microphysiological system as a preclinical model for drug toxicity assessment. To show clinical relevance, we use quantitative systems pharmacology computational models for in vitro-in vivo translation of the experimental results and to identify favorable dosing regimens for one of the tested drugs.
药物性肾损伤是急性肾损伤的主要原因,可导致进行性肾病,并与住院患者死亡率升高有关。药物性肾损伤的主要损伤部位是近端肾小管。临床上,监测肾损伤分子-1(一种已确立的肾小管特异性生物标志物)以评估损伤的存在和进展。在临床前准确预测药物相关性肾毒性的能力将降低患者负担和药物淘汰率,但最先进的体外和动物模型未能做到这一点。在这项研究中,我们展示了在肾脏微生理系统中使用肾损伤分子-1 测量作为药物毒性评估的临床前模型。为了显示临床相关性,我们使用定量系统药理学计算模型将实验结果进行体外-体内转化,并确定其中一种测试药物的有利给药方案。